New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s ...

Series A financing co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy for Angelman syndrome, is ...

The global Antisense Oligonucleotides Market is expected to generate US$ 5,659.2 million in revenue by 2032, up from US$ 1,921.6 million in 2022, with a CAGR of 10.3% over the forecast period.

Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Antisense Oligonucleotide Therapeutics Market by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies: Industry ...

"Antisense Oligonucleotide Therapeutics Pipeline Insights"The Antisense Oligonucleotide landscape features 70+ key companies, including Novartis, Wave Life Sciences, Bio-Path Holdings, and others, ...

When LINE-1 RNA was depleted in human progeroid cells using antisense oligonucleotides the senescent phenotypes were ameliorated, while in the premature aging mouse model this therapy restored tissue ...